The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer's disease

Marina Saresella, Francesca La Rosa, Federica Piancone, Martina Zoppis, Ivana Marventano, Elena Calabrese, Veronica Rainone, Raffaello Nemni, Roberta Mancuso, Mario Salvatore Clerici

Research output: Contribution to journalArticle

Abstract

Background: Interleukin-1 beta (IL-1β) and its key regulator, the inflammasome, are suspected to play a role in the neuroinflammation observed in Alzheimer's disease (AD); no conclusive data are nevertheless available in AD patients. Results: mRNA for inflammasome components (NLRP1, NLRP3, PYCARD, caspase 1, 5 and 8) and downstream effectors (IL-1β, IL-18) was up-regulated in severe and MILD AD. Monocytes co-expressing NLRP3 with caspase 1 or caspase 8 were significantly increased in severe AD alone, whereas those co-expressing NLRP1 and NLRP3 with PYCARD were augmented in both severe and MILD AD. Activation of the NLRP1 and NLRP3 inflammasomes in AD was confirmed by confocal microscopy proteins co-localization and by the significantly higher amounts of the pro-inflammatory cytokines IL-1 β and IL-18 being produced by monocytes. In MCI, the expression of NLRP3, but not the one of PYCARD or caspase 1 was increased, indicating that functional inflammasomes are not assembled in these individuals: this was confirmed by lack of co-localization and of proinflammatory cytokines production. Conclusions: The activation of at least two different inflammasome complexes explains AD-associated neuroinflammation. Strategies targeting inflammasome activation could be useful in the therapy of AD.

Original languageEnglish
Article number23
JournalMolecular Neurodegeneration
Volume11
Issue number1
DOIs
Publication statusPublished - 2016

Fingerprint

Inflammasomes
Caspase 1
Caspase 8
Alzheimer Disease
Interleukin-1beta
Interleukin-18
Monocytes
Cytokines
Confocal Microscopy
Messenger RNA

Keywords

  • Alzheimer's disease
  • Beta amyloid
  • Inflammasome
  • Mild cognitive impairment
  • Neuroinflammation

ASJC Scopus subject areas

  • Molecular Biology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer's disease. / Saresella, Marina; La Rosa, Francesca; Piancone, Federica; Zoppis, Martina; Marventano, Ivana; Calabrese, Elena; Rainone, Veronica; Nemni, Raffaello; Mancuso, Roberta; Clerici, Mario Salvatore.

In: Molecular Neurodegeneration, Vol. 11, No. 1, 23, 2016.

Research output: Contribution to journalArticle

@article{bb7cad0ea6c8468db36351e906d60b3d,
title = "The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer's disease",
abstract = "Background: Interleukin-1 beta (IL-1β) and its key regulator, the inflammasome, are suspected to play a role in the neuroinflammation observed in Alzheimer's disease (AD); no conclusive data are nevertheless available in AD patients. Results: mRNA for inflammasome components (NLRP1, NLRP3, PYCARD, caspase 1, 5 and 8) and downstream effectors (IL-1β, IL-18) was up-regulated in severe and MILD AD. Monocytes co-expressing NLRP3 with caspase 1 or caspase 8 were significantly increased in severe AD alone, whereas those co-expressing NLRP1 and NLRP3 with PYCARD were augmented in both severe and MILD AD. Activation of the NLRP1 and NLRP3 inflammasomes in AD was confirmed by confocal microscopy proteins co-localization and by the significantly higher amounts of the pro-inflammatory cytokines IL-1 β and IL-18 being produced by monocytes. In MCI, the expression of NLRP3, but not the one of PYCARD or caspase 1 was increased, indicating that functional inflammasomes are not assembled in these individuals: this was confirmed by lack of co-localization and of proinflammatory cytokines production. Conclusions: The activation of at least two different inflammasome complexes explains AD-associated neuroinflammation. Strategies targeting inflammasome activation could be useful in the therapy of AD.",
keywords = "Alzheimer's disease, Beta amyloid, Inflammasome, Mild cognitive impairment, Neuroinflammation",
author = "Marina Saresella and {La Rosa}, Francesca and Federica Piancone and Martina Zoppis and Ivana Marventano and Elena Calabrese and Veronica Rainone and Raffaello Nemni and Roberta Mancuso and Clerici, {Mario Salvatore}",
year = "2016",
doi = "10.1186/s13024-016-0088-1",
language = "English",
volume = "11",
journal = "Molecular Neurodegeneration",
issn = "1750-1326",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer's disease

AU - Saresella, Marina

AU - La Rosa, Francesca

AU - Piancone, Federica

AU - Zoppis, Martina

AU - Marventano, Ivana

AU - Calabrese, Elena

AU - Rainone, Veronica

AU - Nemni, Raffaello

AU - Mancuso, Roberta

AU - Clerici, Mario Salvatore

PY - 2016

Y1 - 2016

N2 - Background: Interleukin-1 beta (IL-1β) and its key regulator, the inflammasome, are suspected to play a role in the neuroinflammation observed in Alzheimer's disease (AD); no conclusive data are nevertheless available in AD patients. Results: mRNA for inflammasome components (NLRP1, NLRP3, PYCARD, caspase 1, 5 and 8) and downstream effectors (IL-1β, IL-18) was up-regulated in severe and MILD AD. Monocytes co-expressing NLRP3 with caspase 1 or caspase 8 were significantly increased in severe AD alone, whereas those co-expressing NLRP1 and NLRP3 with PYCARD were augmented in both severe and MILD AD. Activation of the NLRP1 and NLRP3 inflammasomes in AD was confirmed by confocal microscopy proteins co-localization and by the significantly higher amounts of the pro-inflammatory cytokines IL-1 β and IL-18 being produced by monocytes. In MCI, the expression of NLRP3, but not the one of PYCARD or caspase 1 was increased, indicating that functional inflammasomes are not assembled in these individuals: this was confirmed by lack of co-localization and of proinflammatory cytokines production. Conclusions: The activation of at least two different inflammasome complexes explains AD-associated neuroinflammation. Strategies targeting inflammasome activation could be useful in the therapy of AD.

AB - Background: Interleukin-1 beta (IL-1β) and its key regulator, the inflammasome, are suspected to play a role in the neuroinflammation observed in Alzheimer's disease (AD); no conclusive data are nevertheless available in AD patients. Results: mRNA for inflammasome components (NLRP1, NLRP3, PYCARD, caspase 1, 5 and 8) and downstream effectors (IL-1β, IL-18) was up-regulated in severe and MILD AD. Monocytes co-expressing NLRP3 with caspase 1 or caspase 8 were significantly increased in severe AD alone, whereas those co-expressing NLRP1 and NLRP3 with PYCARD were augmented in both severe and MILD AD. Activation of the NLRP1 and NLRP3 inflammasomes in AD was confirmed by confocal microscopy proteins co-localization and by the significantly higher amounts of the pro-inflammatory cytokines IL-1 β and IL-18 being produced by monocytes. In MCI, the expression of NLRP3, but not the one of PYCARD or caspase 1 was increased, indicating that functional inflammasomes are not assembled in these individuals: this was confirmed by lack of co-localization and of proinflammatory cytokines production. Conclusions: The activation of at least two different inflammasome complexes explains AD-associated neuroinflammation. Strategies targeting inflammasome activation could be useful in the therapy of AD.

KW - Alzheimer's disease

KW - Beta amyloid

KW - Inflammasome

KW - Mild cognitive impairment

KW - Neuroinflammation

UR - http://www.scopus.com/inward/record.url?scp=85007417755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007417755&partnerID=8YFLogxK

U2 - 10.1186/s13024-016-0088-1

DO - 10.1186/s13024-016-0088-1

M3 - Article

AN - SCOPUS:85007417755

VL - 11

JO - Molecular Neurodegeneration

JF - Molecular Neurodegeneration

SN - 1750-1326

IS - 1

M1 - 23

ER -